This is a 12-month, multicentre randomised double-blind placebo-controlled Phase IIb study in
patients with mild Alzheimer's dementia (AD). Patients will be randomised on a 1:1 ratio to
receive liraglutide or matching placebo.
Phase:
Phase 2
Details
Lead Sponsor:
Imperial College London
Collaborators:
Avon and Wiltshire Mental Health Partnership NHS Trust King's College Hospital NHS Trust University of Oxford University of Southampton